Thirty-day safety and efficacy of prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for non-urgent indications and anticoagulated with bivalirudin

Conclusion At 30days, there were no differences in MACE or bleeding complications in patients anticoagulated with bivalirudin and given either clopidogrel or prasugrel during PCI for non-urgent indications.
Source: IJC Metabolic and Endocrine - Category: Endocrinology Source Type: research